Skip to main content
Clinical Trials/NCT04292041
NCT04292041
Unknown
Not Applicable

Fasting Mimicking Diet in Prostate Cancer and Metabolic Syndrome, a Pilot Study

Galway Clinic1 site in 1 country40 target enrollmentJanuary 15, 2019

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Prostate Cancer
Sponsor
Galway Clinic
Enrollment
40
Locations
1
Primary Endpoint
Change in Baseline Weight (in kilograms) at 6 months
Last Updated
6 years ago

Overview

Brief Summary

This is a prospective observational cohort study of patients with prostate cancer who have a metabolic syndrome. The study aims to evaluate the role of intermittent fasting (fasting mimicking diet) in these patients. The primary end point is metabolic health and the secondary endpoint is quality of life.

Detailed Description

Cancer is a complex set of conditions which collectively comprise the second biggest cause of death in the western world. In addition, these diseases, along with their various treatments, are associated with significant illness, as well as a host of debilitating symptoms. Two very common problems are cancer fatigue, as well as metabolic changes which can cause much suffering in and of themselves. Patients with advanced cancers, as well as many patients undergoing surgery, radiation therapy as well as chemotherapy all complain of fatigue, to a greater or lesser extent. Many gain or lose weight, and develop associated metabolic changes in uninvolved body systems, which can cause a significant health burden on the patients, as well as the healthcare system as a whole. Little is known about the mechanisms which underlie these symptoms. Various biologic processes have been implicated including inflammation and other changes in body metabolism. There is urgent need to better understand these processes, which cause so much suffering in cancer patients, so as to potentially develop more effective solutions.

Registry
clinicaltrials.gov
Start Date
January 15, 2019
End Date
June 15, 2020
Last Updated
6 years ago
Study Type
Observational
Sex
Male

Investigators

Sponsor
Galway Clinic
Responsible Party
Principal Investigator
Principal Investigator

Professor Frank Sullivan

Medical Director, Department of Radiation Oncology

Galway Clinic

Eligibility Criteria

Inclusion Criteria

  • Patients with biopsy-proven prostate cancer having features of a metabolic syndrome, receiving standard treatment options for their disease.

Exclusion Criteria

  • Patients without a diagnosis of prostate cancer
  • Life expectancy less than 1 year
  • Children under the age of 18
  • Individuals who are allergic to nuts or soy
  • Individuals with a Body Mass Index (BMI) \<18.5
  • Individuals who have been severely weakened by a disease or medical procedure
  • Individuals who are taking medications which may not be safely consumed with a calorie restricted diet unless authorised in writing by a licensed physician
  • Individuals with a history of significant cardiac disease, particularly uncompensated congestive heart failure NYHA grade 2 or more or LVEF \<40% on any prior assessment
  • Individuals with a history of syncope (fainting) with calorie restriction or other medical co-morbidities
  • Individuals who have special dietary needs that are incompatible with the ProLon® meal plan

Outcomes

Primary Outcomes

Change in Baseline Weight (in kilograms) at 6 months

Time Frame: Baseline and 3 months after Nutritional Cycle 3 (each cycle is 4 days per month), about 6 months

Metabolic health parameter

Change in Baseline Blood Pressure (in millimeters of Mercury) at 6 months

Time Frame: Baseline and 3 months after Nutritional Cycle 3 (each cycle is 4 days per month), about 6 months

Metabolic health parameter

Change in Baseline Waist Circumference (in centimeters) at 6 months

Time Frame: Baseline and 3 months after Nutritional Cycle 3 (each cycle is 4 days per month), about 6 months

Metabolic health parameter

Change in Baseline Triglycerides Level (in millimoles per litre) at 6 months

Time Frame: Baseline and 3 months after Nutritional Cycle 3 (each cycle is 4 days per month), about 6 months

Clinical lab results

Change in Baseline Total, LDL, and HDL Cholesterol (in millimoles per litre) at 6 months

Time Frame: Baseline and 3 months after Nutritional Cycle 3 (each cycle is 4 days per month), about 6 months

Clinical lab results

Secondary Outcomes

  • Change in Baseline EQ5D5L Vertical Visual Analogue Scale Score at 6 months(Baseline and 3 months after Nutritional Cycle 3 (each cycle is 4 days per month), about 6 months)
  • Change in Baseline EQ5D5L Health Questionnaire Score at 6 months(Baseline and 3 months after Nutritional Cycle 3 (each cycle is 4 days per month), about 6 months)
  • Change in Baseline Chalder Fatigue Index Score at 6 months(Baseline and 3 months after Nutritional Cycle 3 (each cycle is 4 days per month), about 6 months)

Study Sites (1)

Loading locations...

Similar Trials